Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NPAS2 CRISPR Activation Plasmid (h): sc-405236-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NPAS2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- NPAS2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by NPAS2 CRISPR Activation Plasmid (h) and NPAS2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the NPAS2 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NPAS2 Antibody (FT-68): sc-134404
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NPAS2 CRISPR Activation Plasmid (h) | sc-405236-ACT | 20 µg | $397.00 | |||
NPAS2 CRISPR Activation Plasmid (h2) | sc-405236-ACT-2 | 20 µg | $397.00 |
Human NPAS2 (neuronal PAS domain protein 2) is a basic helix–loop–helix PAS transcription factor that functions as a core component of the molecular circadian clock. NPAS2 heterodimerizes with ARNTL/BMAL1 to bind E-box elements and drive rhythmic transcriptional programs governing sleep–wake timing, metabolism, hormonal signaling, and neuronal excitability. Through transcriptional control of clock-controlled genes, NPAS2 integrates environmental and cellular cues with pathways such as circadian entrainment and energy homeostasis. Dysregulation of NPAS2-associated transcriptional networks has been linked to altered circadian behavior and has been studied in contexts including neuropsychiatric phenotypes, metabolic traits, and cancer-associated clock disruption.
NPAS2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous NPAS2 expression without altering the underlying DNA sequence.
NPAS2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the NPAS2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the NPAS2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous NPAS2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native NPAS2 locus and enabling the study of NPAS2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of NPAS2 pathway restoration in tumor cells with silenced or reduced NPAS2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.